M Emad; Sh Aghaei; P Jafari
Volume 8, Issue 3 , 2005, , Pages 211-217
Abstract
Background: Highly variable results of topical immunotherapy with Diphencyprone (DPC) in the treatment of Alopecia areata have been reported so far. Objective: The purpose of this study was to evaluate the efficacy and tolerability of DPC in the treatment of severe and chronic chronic Alopecia areata. ...
Read More
Background: Highly variable results of topical immunotherapy with Diphencyprone (DPC) in the treatment of Alopecia areata have been reported so far. Objective: The purpose of this study was to evaluate the efficacy and tolerability of DPC in the treatment of severe and chronic chronic Alopecia areata. Patients and Methods: 28 patients (16 female and 12 male, 10-35 years old, mean age 25 years) with chronic and/or extensive Alopecia areata were enrolled in an open-label clinical trial. After sensitization with 2% DPC, progressively higher concentrations beginning at 0.001% were applied weekly for 6 months to one side of the scalp. The maximum concentration of DPC was 2%. Results: 27 of 28 patients completed therapy. The overall response rate was 81.5% (22 cases). Complete response (90%-100% terminal hair re-growth) was obtained in 22.2% (6 cases) and partial response (10%-90% terminal hair re-growth) in 59.3% (16 cases), and 18.5% (5 cases) showed no regrowth. In all patients an eczematous reaction consisting of erythema, itching, and scaling at the site of application was observed. Other observed side effects included occipital lymphadenopathy in 40.7% (11 cases), severe eczema/blister formation in 40.7% (11 cases), hyperpigmentation in 18.5% (5 cases). Notably, partial recurrence was observed in 66.7% (18 cases) of these patients after 6 to 12 months of follow up. Conclusion: Topical DPC treatment for Alopecia areata is an effective therapy with a relatively high relapse rate.
L Dastgheib; M Aziz Zadeh; P Jafari
Volume 8, Issue 2 , 2005, , Pages 88-92
Abstract
Background: Tinea capitis is a relatively common fungal infection in children. Although several oral anti-fungal agents have been used in the treatment of tinea capitis, griseofulvin has been considered as the treatment of choice for a long time. Objective: To compare the therapeutic effects of fluconazole ...
Read More
Background: Tinea capitis is a relatively common fungal infection in children. Although several oral anti-fungal agents have been used in the treatment of tinea capitis, griseofulvin has been considered as the treatment of choice for a long time. Objective: To compare the therapeutic effects of fluconazole with griseofulvin on tinea capitis. Patients and Methods: Through a randomized, single-blinded, clinical trial on 40 clinically suspected an mycologically confirmed tinea capitis cases, 19 cases received oral fluconazole for 4 weeks and 21 patients were treated with griseofulvin for 6 weeks. All patients were evaluated clinically and mycologically before receiving their treatment and 8 weeks after the beginning of treatment. Results: The age range of the patients was from 1 to 16 years. Thirty-two cases were males. Mycology studies indicated that the causative agents were trichophyton verrucosum in 16 cases, trichophyton violaceum in 16 cases and microporum canis in 8 cases. At the end of the eighth week of the beginning of treatment, 15 cases were cured in the fluconazole group compared with 16 cases in the griseofulvin group (P>0.05). Conclusion: It seems that griseofulvin could be still considered as the first choice drug in the treatment of tinea capitis and fluconazole could be used as an alternative drug.